Start-up launches out of stealth in bid to ‘transform’ women’s health

Cercle, a San Francisco AI start-up focused on advancing women’s healthcare, has launched out of stealth.

Cercle says it aims to harmonise and transform “the raw and fragmented” medical data into accurate insights that help improve patient outcomes.

Its tech platform, Cercle Biomedical Graph, claims to be the only one of its kind harnessing and connecting anonymised biomedical and genomics data points drawn from healthcare clinics and research labs around the world.

The company argues that the data insights collected through its platform could have the potential to speed up medical discoveries in the pharmaceutical and research fields, accelerate precision medicine and treatments and help clinics improve the efficiency and effectiveness of medical care.

“We believe a healthy life is a right, not a privilege,” explains Juan Carlos Riveiro, co-founder and CEO of Cercle.

“Instead of continuing to collect cobwebs, the world’s medical data should be leveraged to generate groundbreaking data-driven insights at speed and scale. These insights can catalyse medical breakthroughs and guide practitioners and patients to better healthcare decisions.

“That’s the founding mission behind Cercle, to personalise and contextualise biomedical and genomics information so women can make better, more informed health decisions,” he adds.

“We are starting with the fertility market, and our long-term goal is to radically improve healthcare equity for women across the world.”

Kate Devine, medical director and chief research officer at US Fertility who has partnered with Cercle, says: “USF’s partnership with Cercle has helped us organise unstructured, de-identified clinical data for analysis. This is optimising our research and internal quality assurance capabilities – maximising accuracy, completeness, and efficiency.

“As a field, fertility medicine has dramatically improved and matured to the point of high success over a short time period.

“My hope is that AI tools will help us cross the next threshold of success in terms of patient outcomes, patient experience and optimising efficiency so that we can expand access to fertility care to everyone who needs it.”

Marco Barbierato, managing director of Eurofins Genoma who has also partnered with Cercle, says: “Eurofins Genoma is optimistic about the use of AI in healthcare.

“The technology that Cercle leverages within its biomedical graph allows for efficient insights that clinics Eurofins Genoma serves did not have access to previously.

“This will support the genetics industry to take a step towards contributing to improving overall health outcomes.”